reports
- Patrick Steiner
APAML APERAM SA
ACN ACCENTURE PLC CLASS A
EXE EXEL INDUSTRIES SA
INF INFOTEL SA
EVN EVN AG
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
COTN COMET HOLDING AG
CAP CAPGEMINI SE
TXGN TX GROUP AG
DEZ DEUTZ AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
CIE CIE AUTOMOTIVE S.A.
LFDE LA FRANCAISE DE L'ENERGIE SA
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
IFCN INFICON HOLDING AG
- Patrick Steiner
APAML APERAM SA
ACN ACCENTURE PLC CLASS A
EXE EXEL INDUSTRIES SA
INF INFOTEL SA
EVN EVN AG
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
COTN COMET HOLDING AG
CAP CAPGEMINI SE
TXGN TX GROUP AG
DEZ DEUTZ AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
CIE CIE AUTOMOTIVE S.A.
LFDE LA FRANCAISE DE L'ENERGIE SA
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
IFCN INFICON HOLDING AG
- Ghada Ben Sedrine
- Nicolas David
ADP AEROPORTS DE PARIS SA
SOP SOPRA STERIA GROUP SA
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
KER KERING SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
HM B H&M HENNES & MAURITZ AB CLASS B
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
BP. BP P.L.C.
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
DSY DASSAULT SYSTEMES SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Ghada Ben Sedrine
- Nicolas David
ADP AEROPORTS DE PARIS SA
SOP SOPRA STERIA GROUP SA
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
KER KERING SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
HM B H&M HENNES & MAURITZ AB CLASS B
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
BP. BP P.L.C.
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
DSY DASSAULT SYSTEMES SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Nicolas David
- Nicolas Thorez
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Nicolas David
- Nicolas Thorez
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Thera...
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a potential new therapeutic approach for difficult-to-treat cancers: No dose limiting toxicity reached to date, enabling recruitment of a third patient cohortGNS561 and MEKi combination demonstrated disease stabilization in all evaluable patients with evidence of tumor shrinkage in a subset of patients, warrant...
GENFIT : GNS561 montre une activité antitumorale prometteuse en combin...
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique Données préliminaires très encourageantes de l’étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, positionnant cette combinaison innovante comme une nouvelle approche thérapeutique potentielle pour les cancers difficiles à traiter : Pas de toxicité dose-limitante observée à ce jour, permettant la poursuite du recrutement d’une troisième cohorte de patientsLa combinaison GNS561 + MEKi a démontré...
Bonduelle: 1 director
A director at Bonduelle bought 33,358 shares at 9.991EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
BONDUELLE - Monthly statement of the number of shares and voting right...
BONDUELLE - Monthly statement of the number of shares and voting rights BONDUELLE Head office: "La Woestyne" - 59173 Renescure - FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number: 447 250 044 (Dunkerque Commercial and Companies Register) MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE COMPANY’S SHARE CAPITAL ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FINANCIAL MARKET AUTHORITY Date of the latest informationTotal number of shares forming capitalNumber of voting rights30....
BONDUELLE - Déclaration mensuelle du nombre d'actions et de droits de ...
BONDUELLE - Déclaration mensuelle du nombre d'actions et de droits de vote BONDUELLE Siège social - "La Woestyne" - 59173 Renescure - FranceBonduelle SCA - Société en commandite par actions au capital de 57 102 699,50 eurosRCS DUNKERQUE 447 250 044 INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DES DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL ARTICLE 223-16 DU REGLEMENT GENERAL DE L’AUTORITE DES MARCHES FINANCIERS Date d’arrêté des informationsNombre total d’actions composant le capital Nombre total de droits de vote30.11.202532 630 114Total théorique 52 559 755 Total réel* ...
Marie Brizard Wine & Spirits Monthly declaration of the total number o...
Marie Brizard Wine & Spirits Monthly declaration of the total number of voting rights and shares MONTHLY DECLARATION OF THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES (ARTICLE L233-8II THE COMMERCIAL CODE and 223-16 OF THE GENERAL REGULATIONS OF THE FINANCIAL MARKETS AUTHORITY (AMF)) Charenton-le-Pont, 3rd December 2025 MARIE BRIZARD WINE & SPIRITS ISIN Code: 0000060873 Situation at:Total number of shares comprising share capitalTotal number of voting rights30 November 2025111 989 823Number of voting rights (1): 194 037 742Number of exercisable voting rights (2): 193 902 046 Do the Marie...
Marie Brizard Wine & Spirits Déclaration mensuelle relative au nombre ...
Marie Brizard Wine & Spirits Déclaration mensuelle relative au nombre total de droits de vote et d'actions DECLARATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS (ARTICLE L233-8II DU CODE DE COMMERCE et 223-16 DU REGLEMENT GENERAL DE L’AUTORITE DES MARCHES FINANCIERS) Charenton-le-Pont, le 3 décembre 2025 MARIE BRIZARD WINE & SPIRITS Code ISIN : 0000060873 Situation au :Nombre total d’actions composant le capital socialNombre total de droits de votes30 novembre 2025111 989 823Nombre de droits de vote théoriques (1) : 194 037 742Nombre de droits de vote exerçables ...
GENFIT Announces Appointment of new Chief Medical Officer
GENFIT Announces Appointment of new Chief Medical Officer Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT. Member of the Executive Committee, Dr. Motlagh will oversee the strategy, direction, and execution of GENFIT’s clinical development plans and lead the Clinical (Operations and Strategy), Biometri...
GENFIT annonce la nomination d’un nouveau Directeur Médical
GENFIT annonce la nomination d’un nouveau Directeur Médical Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 27 novembre 2025 – GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la nomination du Dr. Pejvack Motlagh en tant que nouveau Directeur Médical de GENFIT. Membre du Comité Exécutif, le Dr Motlagh supervisera la stratégie, l’orientation et l’exécution des plans de développement clinique de GENFIT, et dirigera les équi...
- Klaus Ringel
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
ORA ORANGE SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
EN BOUYGUES SA
TNG TRANSGENE SA
SZG SALZGITTER AG
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
VOE VOESTALPINE AG
BOSS HUGO BOSS AG
ACX ACERINOX SA
TRI TRIGANO SA
DEZ DEUTZ AG
CAI CA IMMOBILIEN ANLAGEN AG
UBS UBM DEVELOPMENT AG
SAFE SAFESTORE HOLDINGS PLC
AEDAS AEDAS HOMES SA
GRE GRENERGY RENOVABLES
DSPW DOOSAN SKODA POWER A.S.
FERGR FERRARI GROUP PUBLIC LIMITED COMPANY
HBX HBX GROUP INTERNATIONAL PLC
LOUP SOCIETE L.D.C.
- Martin Marandon-Carlhian
- Stephane Houri
VIE VEOLIA ENVIRONNEMENT SA
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
ORA ORANGE SA
SSAB A SSAB AB CLASS A
EN BOUYGUES SA
SZG SALZGITTER AG
CDR CD PROJEKT S.A.
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
HAL HAL TRUST
VOE VOESTALPINE AG
ACX ACERINOX SA
ITX INDUSTRIA DE DISENO TEXTIL S.A.
SHL SIEMENS HEALTHINEERS AG
ATCO A ATLAS COPCO AB
- Martin Marandon-Carlhian
- Stephane Houri
VIE VEOLIA ENVIRONNEMENT SA
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
ORA ORANGE SA
SSAB A SSAB AB CLASS A
EN BOUYGUES SA
SZG SALZGITTER AG
CDR CD PROJEKT S.A.
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
HAL HAL TRUST
VOE VOESTALPINE AG
ACX ACERINOX SA
ITX INDUSTRIA DE DISENO TEXTIL S.A.
SHL SIEMENS HEALTHINEERS AG
ATCO A ATLAS COPCO AB
- Klaus Ringel
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
ORA ORANGE SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
EN BOUYGUES SA
TNG TRANSGENE SA
SZG SALZGITTER AG
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
VOE VOESTALPINE AG
BOSS HUGO BOSS AG
ACX ACERINOX SA
TRI TRIGANO SA
DEZ DEUTZ AG
CAI CA IMMOBILIEN ANLAGEN AG
UBS UBM DEVELOPMENT AG
SAFE SAFESTORE HOLDINGS PLC
AEDAS AEDAS HOMES SA
GRE GRENERGY RENOVABLES
DSPW DOOSAN SKODA POWER A.S.
FERGR FERRARI GROUP PUBLIC LIMITED COMPANY
HBX HBX GROUP INTERNATIONAL PLC
LOUP SOCIETE L.D.C.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.